îāļāđāļāļŦāļē
îž
î
āļĨāđāļāļāļāļīāļ
îāļāđāļāļŦāļē
î
Abbott Laboratories
ABT102.870USD
+0.490+0.48%
āļāļīāļÂ 04/02, 16:00ïžETïžāļĢāļēāļāļēāļĨāđāļēāļāđāļē 15 āļāļēāļāļĩ
161.85BāļĄāļđāļĨāļāđāļēāļāļĨāļēāļ
27.45P/E TTM
î
āļĢāļēāļĒāļĨāļ°āđāļāļĩāļĒāļāđāļāļīāđāļĄāđāļāļīāļĄāļāļāļ Abbott Laboratories āļāļĢāļīāļĐāļąāļ
Abbott Laboratories is a global healthcare company. The Companyâs principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
āļāđāļāļĄāļđāļĨ Abbott Laboratories
îāļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļABT
āļāļ·āđāļāļāļĢāļīāļĐāļąāļAbbott Laboratories
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļApr 06, 2073
āļāļĩāļāļĩāđāļFord (Robert B)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ114000
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļApr 06
āļāļĩāđāļāļĒāļđāđ100 Abbott Park Road
āđāļĄāļ·āļāļABBOTT PARK
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX NASDAQ Basic NYSE
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ60064-3500
āđāļāļĢāļĻāļąāļāļāđ12246676100
āđāļ§āđāļāđāļāļāđhttps://www.abbott.com
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļABT
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļApr 06, 2073
āļāļĩāļāļĩāđāļFord (Robert B)
āļāļđāđāļāļĢāļīāļŦāļēāļĢāļāļĢāļīāļĐāļąāļāļāļāļ Abbott Laboratories
îāļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Mr. Daniel J. Starks
Mr. Daniel J. Starks
Independent Director
Independent Director
6.74M
+0.15%
Mr. Daniel Gesua Sive Salvadori
Mr. Daniel Gesua Sive Salvadori
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
146.38K
-0.60%
Ms. Mary K. Moreland
Ms. Mary K. Moreland
Executive Vice President - Human Resources
Executive Vice President - Human Resources
104.29K
-0.59%
Ms. Lisa D. Earnhardt
Ms. Lisa D. Earnhardt
Executive Vice President, Group President - Medical Devices
Executive Vice President, Group President - Medical Devices
90.41K
+20.44%
Mr. Louis H. (Lou) Morrone
Mr. Louis H. (Lou) Morrone
Executive Vice President - Core Diagnostics
Executive Vice President - Core Diagnostics
76.84K
-1.49%
Mr. Philip P. Boudreau
Mr. Philip P. Boudreau
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
71.54K
+28.74%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
40.80K
--
Ms. Sally E. Blount, Ph.D.
Ms. Sally E. Blount, Ph.D.
Independent Director
Independent Director
34.06K
--
Mr. John G. Stratton
Mr. John G. Stratton
Independent Director
Independent Director
19.03K
--
Ms. Michelle A. Kumbier
Ms. Michelle A. Kumbier
Independent Director
Independent Director
15.71K
--
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Mr. Daniel J. Starks
Mr. Daniel J. Starks
Independent Director
Independent Director
6.74M
+0.15%
Mr. Daniel Gesua Sive Salvadori
Mr. Daniel Gesua Sive Salvadori
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
146.38K
-0.60%
Ms. Mary K. Moreland
Ms. Mary K. Moreland
Executive Vice President - Human Resources
Executive Vice President - Human Resources
104.29K
-0.59%
Ms. Lisa D. Earnhardt
Ms. Lisa D. Earnhardt
Executive Vice President, Group President - Medical Devices
Executive Vice President, Group President - Medical Devices
90.41K
+20.44%
Mr. Louis H. (Lou) Morrone
Mr. Louis H. (Lou) Morrone
Executive Vice President - Core Diagnostics
Executive Vice President - Core Diagnostics
76.84K
-1.49%
Mr. Philip P. Boudreau
Mr. Philip P. Boudreau
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
71.54K
+28.74%
āļŠāļąāļāļŠāđāļ§āļāļāļāļāļĢāļēāļĒāđāļāđ
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: 6 āļāļąāđāļ§āđāļĄāļāļāļĩāđāđāļĨāđāļ§
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: 6 āļāļąāđāļ§āđāļĄāļāļāļĩāđāđāļĨāđāļ§
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
Diabetes Care
8.00B
18.04%
Core Laboratory
5.36B
12.09%
Adult Nutritionals
4.48B
10.10%
Key Emerging Markets
4.17B
9.40%
Pediatric Nutritionals
3.97B
8.96%
āļāļ·āđāļ āđ
18.35B
41.40%
āļāļēāļĄāļ āļđāļĄāļīāļ āļēāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
United States
17.13B
38.63%
All other Countries
15.98B
36.05%
Germany
2.76B
6.22%
China
1.91B
4.30%
India
1.87B
4.22%
āļāļ·āđāļ āđ
4.69B
10.57%
āļāļēāļĄāļāļļāļĢāļāļīāļ
āļāļēāļĄāļ āļđāļĄāļīāļ āļēāļ
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
Diabetes Care
8.00B
18.04%
Core Laboratory
5.36B
12.09%
Adult Nutritionals
4.48B
10.10%
Key Emerging Markets
4.17B
9.40%
Pediatric Nutritionals
3.97B
8.96%
āļāļ·āđāļ āđ
18.35B
41.40%
āļŠāļāļīāļāļīāļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļĪāļŦāļąāļŠāļāļĩāđ 19 āļ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļĪāļŦāļąāļŠāļāļĩāđ 19 āļ.āļ.
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
The Vanguard Group, Inc.
10.06%
BlackRock Institutional Trust Company, N.A.
5.34%
State Street Investment Management (US)
4.60%
Capital International Investors
3.64%
Capital Research Global Investors
2.25%
āļāļ·āđāļ āđ
74.11%
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
The Vanguard Group, Inc.
10.06%
BlackRock Institutional Trust Company, N.A.
5.34%
State Street Investment Management (US)
4.60%
Capital International Investors
3.64%
Capital Research Global Investors
2.25%
āļāļ·āđāļ āđ
74.11%
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
Investment Advisor
47.07%
Investment Advisor/Hedge Fund
23.66%
Research Firm
3.22%
Pension Fund
2.48%
Bank and Trust
2.27%
Sovereign Wealth Fund
1.41%
Insurance Company
1.01%
Hedge Fund
0.67%
Individual Investor
0.49%
āļāļ·āđāļ āđ
17.73%
āļāļēāļĢāļāļ·āļāļŦāļļāđāļāļāļāļāļŠāļāļēāļāļąāļ
îāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļļāļāļāļĩāđ 1 āđāļĄ.āļĒ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļļāļāļāļĩāđ 1 āđāļĄ.āļĒ.
āļāđāļ§āļāđāļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļāļēāļ
āļāļģāļāļ§āļāļŠāļāļēāļāļąāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
2026Q1
4783
1.42B
81.98%
-5.95M
2025Q4
4606
1.42B
81.82%
+3.92M
2025Q3
4681
1.42B
81.87%
+8.53M
2025Q2
4668
1.41B
81.51%
+6.23M
2025Q1
4636
1.40B
80.10%
+7.18M
2024Q4
4554
1.38B
78.81%
+33.68M
2024Q3
4367
1.35B
78.83%
-5.95M
2024Q2
4376
1.35B
78.36%
+5.03M
2024Q1
4375
1.35B
77.56%
-1.86M
2023Q4
4400
1.34B
77.62%
+7.10M
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļīāļāļāļĢāļĢāļĄāļāļđāđāļāļ·āļāļŦāļļāđāļ
îāļāļ·āđāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
āđāļāļĨāļĩāđāļĒāļ%
āļ§āļąāļāļāļĩāđ
The Vanguard Group, Inc.
174.89M
10.06%
+2.54M
+1.47%
Nov 28, 2025
BlackRock Institutional Trust Company, N.A.
89.23M
5.13%
+711.43K
+0.80%
Sep 30, 2025
State Street Investment Management (US)
78.23M
4.5%
-128.28K
-0.16%
Sep 30, 2025
Capital International Investors
61.61M
3.54%
+1.48M
+2.46%
Sep 30, 2025
Capital Research Global Investors
38.77M
2.23%
-3.00M
-7.18%
Sep 30, 2025
Geode Capital Management, L.L.C.
38.54M
2.22%
+248.83K
+0.65%
Sep 30, 2025
Norges Bank Investment Management (NBIM)
22.25M
1.28%
+1.27M
+6.03%
Jun 30, 2025
Wellington Management Company, LLP
23.25M
1.34%
-1.80M
-7.20%
Sep 30, 2025
T. Rowe Price Investment Management, Inc.
17.77M
1.02%
+9.40M
+112.38%
Sep 30, 2025
JP Morgan Asset Management
19.25M
1.11%
-7.14M
-27.05%
Sep 30, 2025
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
ETF āļāļĩāđāđāļāļĩāđāļĒāļ§āļāđāļāļ
îāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļļāļāļāļĩāđ 5 āļ.āļĒ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļļāļāļāļĩāđ 5 āļ.āļĒ.
āļāļ·āđāļ
āļŠāļąāļāļŠāđāļ§āļ
iShares U.S. Medical Devices ETF
19.31%
Goldman Sachs Future Health Care Equity ETF
6.26%
SMI 3Fourteen Full-Cycle Trend ETF
5.01%
Invesco Pharmaceuticals ETF
4.99%
Health Care Select Sector SPDR Fund
4.62%
Proshares Ultra Health Care
4.61%
Tema Heart & Health ETF
4.5%
iShares U.S. Healthcare ETF
4.42%
AdvisorShares Focused Equity ETF
4.37%
Polen Capital Global Growth ETF
4.27%
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
iShares U.S. Medical Devices ETF
āļŠāļąāļāļŠāđāļ§āļ19.31%
Goldman Sachs Future Health Care Equity ETF
āļŠāļąāļāļŠāđāļ§āļ6.26%
SMI 3Fourteen Full-Cycle Trend ETF
āļŠāļąāļāļŠāđāļ§āļ5.01%
Invesco Pharmaceuticals ETF
āļŠāļąāļāļŠāđāļ§āļ4.99%
Health Care Select Sector SPDR Fund
āļŠāļąāļāļŠāđāļ§āļ4.62%
Proshares Ultra Health Care
āļŠāļąāļāļŠāđāļ§āļ4.61%
Tema Heart & Health ETF
āļŠāļąāļāļŠāđāļ§āļ4.5%
iShares U.S. Healthcare ETF
āļŠāļąāļāļŠāđāļ§āļ4.42%
AdvisorShares Focused Equity ETF
āļŠāļąāļāļŠāđāļ§āļ4.37%
Polen Capital Global Growth ETF
āļŠāļąāļāļŠāđāļ§āļ4.27%
āđāļāļīāļāļāļąāļāļāļĨ
îāļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
13.90B
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
āļ§āļąāļāļāļĩāđ
āđāļāļīāļāļāļąāļāļāļĨ
āļ§āļąāļāļāļĩāđāļāļąāļāļāļķāļ
āļ§āļąāļāļāļĩāđāļāļģāļĢāļ°āđāļāļīāļ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
Feb 20, 2026
ABT.NB Interim Cash Dividend of gross USD 0.63 paid on May 15, 2026 going ex on Apr 15, 2026 with reinvestment option
Apr 15, 2026
May 15, 2026
Apr 15, 2026
Dec 12, 2025
ABT.NB Final Cash Dividend of gross USD 0.63 paid on Feb 13, 2026 going ex on Jan 15, 2026 with reinvestment option
Jan 15, 2026
Feb 13, 2026
Jan 15, 2026
Sep 19, 2025
ABT.NB Interim Cash Dividend of gross USD 0.59 paid on Nov 17, 2025 going ex on Oct 15, 2025 with reinvestment option
Oct 15, 2025
Nov 17, 2025
Oct 15, 2025
Jun 13, 2025
ABT.NB Interim Cash Dividend of gross USD 0.59 paid on Aug 15, 2025 going ex on Jul 15, 2025 with reinvestment option
Jul 15, 2025
Aug 15, 2025
Jul 15, 2025
Feb 21, 2025
ABT.NB Interim Cash Dividend of gross USD 0.59 paid on May 15, 2025 going ex on Apr 15, 2025 with reinvestment option
Apr 15, 2025
May 15, 2025
Apr 15, 2025
Dec 13, 2024
ABT.NB Final Cash Dividend of gross USD 0.59 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Sep 19, 2024
ABT.NB Final Cash Dividend of gross USD 0.55 paid on Nov 15, 2024 going ex on Oct 15, 2024
Oct 15, 2024
Nov 15, 2024
Oct 15, 2024
Jun 15, 2024
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option
Jul 15, 2024
Aug 15, 2024
Jul 15, 2024
Feb 16, 2024
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on May 15, 2024 going ex on Apr 12, 2024
Apr 15, 2024
May 15, 2024
Apr 12, 2024
Dec 15, 2023
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Feb 15, 2024 going ex on Jan 11, 2024 with reinvestment option
Jan 12, 2024
Feb 15, 2024
Jan 11, 2024
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļēāļĢāđāļāđāļāļŦāļļāđāļ
îāļ§āļąāļāļāļĩāđ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļ§āļąāļāļāļĩāđ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
